Silvia Rossi

Silvia Rossi

Auto-generated profile, based on publicly available information

Silvia Rossi

Division of Rheumatology IRCCS S. Matteo Hospital Foundation Pavia Italy

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Case Reports in Ophthalmological Medicine
Verified
Journal Article
Open access
MMMuhammad Ali Muslimani
Muhammad Ali Muslimani
AAAlberto Ardizzone
Alberto Ardizzone
SRSilvia Rossi
Silvia Rossi
FSFrancesco Siviero
Francesco Siviero
ALArmanda Leka
Armanda Leka
AMAngela Maria Di Matteo
Angela Maria Di Matteo
Background: Ocular tuberculosis (TB) is an uncommon yet potentially vision‐threatening manifestation of Mycobacterium tuberculosis , particularly difficult to diagnose in immunocompromised individuals. The increasing use of anti–tumor necrosis factor‐ α (anti–TNF‐ α ) agents has markedly heightened the risk of TB reactivation, often with disseminated or extrapulmonary involvement despite negative baseline screening. Case Presentation: We describe a 52‐year‐old woman with rheumatoid arthritis receiving long‐term adalimumab and methotrexate who developed disseminated TB with pulmonary, splenic, and ocular involvement after 12 years of anti–TNF‐ α therapy. Baseline screening had shown a negative tuberculin skin test and an indeterminate interferon‐ γ release assay. She presented with constitutional and respiratory symptoms, whereas chest computed tomography demonstrated diffuse micronodular infiltrates consistent with miliary TB. Microbiological confirmation was obtained via bronchoalveolar lavage. Ophthalmologic evaluation revealed bilateral choroidal granulomas with subretinal edema, leading to a diagnosis of ocular TB. Standard antitubercular therapy (ATT) was initiated but required modification due to drug‐induced liver injury. Adjunctive systemic corticosteroids were introduced after antimicrobial therapy and gradually tapered. The patient achieved progressive clinical, radiological, and ophthalmologic improvement, with gradual regression of choroidal lesions. Discussion: This case underscores the persistent long‐term risk of TB reactivation during prolonged anti–TNF‐ α therapy and highlights the limitations of current screening strategies in immunosuppressed patients. Ocular TB requires integration of systemic, clinical, and imaging findings; in this patient, microbiologically confirmed disseminated TB together with characteristic bilateral choroidal granulomas supported a definitive diagnosis. Management relies on prompt ATT, discontinuation of immunosuppression, and judicious use of adjunctive corticosteroids. Long‐term follow‐up is essential given the risk of persistent lesions and late recurrence. Reintroduction of biologic therapy may be feasible in selected cases but requires careful risk stratification. Conclusion: TB should remain a diagnostic consideration in patients receiving biologic therapy who develop compatible systemic or ocular manifestations, even after long‐term treatment and negative baseline screening. Close multidisciplinary collaboration is essential for the diagnosis and management of ocular TB in this population.

1 September 2017 in Canadian Journal of Health History
Verified
Journal Article
Closed access
SRSilvia Rossi
Silvia Rossi

1 June 2015 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
VCV. Codullo
V. Codullo
LCLorenzo Cavagna
Lorenzo Cavagna
Stefano GhioStefano Ghio
Stefano Ghio
CSC.A. Scirè
C.A. Scirè
EGE. Guzzafame
E. Guzzafame
RCRoberto Caporali
Roberto Caporali
Background Among different subgroups of pulmonary arterial hypertension (PAH), those associated with connective tissue diseases (CTDs) are a specific entity with distinct hemodynamic and prognostic features. PAH screening is routinely performed in systemic sclerosis (SSc) and in other CTDs. Conversely, as suggested by international guidelines, it is important to rule out CTDs in patients with PAH, because patients diagnosed as idiopathic PAH (iPAH) may have an associated CTD previously unrecognized. Despite this assumption, no data about this phenomenon have been reported yet. Objectives To analyse frequency and prognosis of undiagnosed CTDs in PAH patients Methods Fifty consecutive patients with PAH confirmed by right heart catheterization referred at the Cardiology Division of our University Hospital without a previous CTD diagnosis, rheumatology assessment or the occurrence of known conditions explaining PAH were evaluated for the frequency of any CTD. Patients underwent complete clinical, laboratory and instrumental evaluation including capillaroscopy and antinuclear antibody (ANA) determination. Current classification criteria were used for the identification of CTD. These patients were subsequently followed-up and their survival has been reported. Statistical analysis was performed using STATA v11. Results Of the 49 patients enrolled (1 patients refused rheumatology assessment), 17 were classified as CTD-PAH (12 SSc, 2 SLE, 2 undifferentiated CTD, 1 Sjögren Syndrome), corresponding to an estimated prevalence (95%CI) of 34.7% (21.7-49.6%). ANA positivity was associated with a sensitivity of 94% (95%CI 71.3-99.9%) and a specificity of 78.1% (60-90.7%) for a diagnosis of CTD-PAH; Raynaud's phenomenon (RP) was associated with a sensitivity of 83.3% (95%CI 51.6-97.9%) and a specificity of 100% (90.5-100%) for a diagnosis of SSc-associated-PAH. At PAH diagnosis, SSc patients were older and had a lower creatinine clearance with respect to both iPAH and other CTD-PAH. Brain Natriuretic Peptide levels were lower in other-CTDs than in SSc and iPAH. NYHA functional class, mean Pulmonary Arterial Pressure (mPAP), cardiac index and pulmonary vascular resistance did not differ between groups. An inverse linear relationship between mPAP and cardiac index was observed in the CTD group. After a median follow-up of 44 (2-132) months, 18/49 (36.7%) patients were deceased: 10/32 (31.2%) in the iPAH group, 1/5 (20%) in the CTD and 7/12 (58.3%) in the SSc-PAH group. Mortality was significantly higher in SSc-PAH (HR 3.07, 1.02-9.23, p<0.05) versus iPAH whilst there was no statistically significant difference between non SSc CTDs and iPAH (Figure 1). Conclusions Our results showed a high prevalence of undiagnosed CTDs, particularly SSc, in patients with iPAH without a previous rheumatological assessment. All patients with RP in our series were diagnosed with SSc. The reported prevalence of RP in iPAH in the literature ranges from 5 to 30% and this might be accounted by the high prevalence of an undiagnosed rheumatic disease in these cohorts. Our data stress the importance of a rheumatological assessment in PAH, especially because of the unfavourable prognostic impact of an associated SSc in these patients. Disclosure of Interest None declared